Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Sponsor: Context Therapeutics Inc.
Summary
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
Official title: A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2024-07-10
Completion Date
2028-04-30
Last Updated
2026-02-20
Healthy Volunteers
No
Interventions
CTIM-76
CLDN6 bispecific Antibody administered weekly (Day 1, 8, 15 and 22) of a 28-day treatment cycle until disease progression.
Locations (13)
University of Arkansas Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas, United States
Precision NextGen Oncology & Research Center
Beverly Hills, California, United States
SCRI at Denver Health
Denver, Colorado, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
John Theurer Cancer Center
Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke Cancer Institute
Durham, North Carolina, United States
Gabrail Cancer Center
Canton, Ohio, United States
Providence Cancer Institute of Oregon
Portland, Oregon, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Women & Infants Hospital of Rhode Island
Providence, Rhode Island, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
SCRI at Mary Crowley
Dallas, Texas, United States